---
title: 'Funding Daily Summary: What Happened on November 13, 2026'
headline: Windward raises $225 million in IPO and Sanofi placement
description: Neurosterix added a $105 million Series B, while NIH outlined a new structure
  for clinical-trial funding announcements.
url: https://thebench.bio/news/funding/2026-11-13
topic: funding
date: '2026-11-13'
covers:
- '2026-11-13'
date_published: '2026-11-13T12:02:56Z'
date_modified: '2026-11-14T00:01:47Z'
tags:
- Funding
- Industry
sources: 6
publisher: TheBench.Bio
---

# Funding Daily Summary: What Happened on November 13, 2026

**Windward raises $225 million in IPO and Sanofi placement**

Neurosterix added a $105 million Series B, while NIH outlined a new structure for clinical-trial funding announcements.

## Today in brief

Windward raised $225 million through a $175 million Nasdaq IPO and a separate $50 million investment from Sanofi. [1] [2] Neurosterix secured $105 million to advance its neuropsychiatric drug pipeline, including a schizophrenia candidate it plans to move into Phase 2. [3] [4]

NIH is developing five clinical-trial funding announcements organized by trial type rather than disease area. [5]

## Windward raises $225 million to fund respiratory and immune-disease drugs

Windward Bio priced about 10.3 million shares at $17 each in its Nasdaq IPO, raising $175 million. [1] [2] Sanofi committed another $50 million in a separate purchase of shares and pre-funded warrants at the IPO price. [1] [2]

The financing supports two licensed candidates, including WIN378, an antibody that targets TSLP, a signaling protein involved in asthma. [1] [2] Windward aims to dose WIN378 every six months. The drug has entered the Phase 3 portion of a Phase 2/3 study in severe, uncontrolled asthma. [2]

Windward plans pivotal asthma studies and expects preliminary results in the first half of 2029. [2] It also expects COPD data for WIN378 and Phase 1 results for WIN027 in 2027. The company estimates its cash will last into the first half of 2029. [1] [2]

## Neurosterix raises $105 million to develop schizophrenia and mood-disorder drugs

Neurosterix raised $105 million in a Series B led by RTW Investments. Janus Henderson Investors, GV and Acorn Bioventures also participated. [3]

The company plans to advance NTX-253, an oral drug designed to amplify signaling through the muscarinic M4 receptor, into Phase 2 for schizophrenia. [3] [4] Neurosterix said it completed Phase 1 studies in healthy volunteers and people with stable schizophrenia in October. Pharmacokinetic results support once-daily dosing, the company said. [4]

The studies have not demonstrated clinical efficacy, Neurosterix said. [4] The financing will also support NTX-819 for mood and anxiety disorders and NTX-529 for psychosis and mood-related conditions. [3] [4]

## NIH is preparing five trial-type funding announcements

The National Institutes of Health is developing five shared clinical-trial funding announcements grouped by trial design rather than disease. [5] The categories will cover feasibility, early-to-definitive, multisite, pragmatic and implementation, and network trials, according to NIH. [5]

NIH says the announcements should standardize guidance for similar studies and help researchers identify suitable funding routes. [5] They will supplement existing broad R01 and R21 announcements and roll out in stages. Institutes can still issue targeted trial calls when needed. [5]

Elizabeth Ginexi warned that fewer targeted calls could weaken funding signals for overlooked research areas. Granted AI said new investigators may find it harder to identify the right submission route. [5]

## Also worth knowing

- Five neurology-focused startups raised about $450 million combined in recent weeks. [6]

## The day in numbers

- **$225 million**: Windward's combined IPO and Sanofi private-placement proceeds. [1] [2]
- **$105 million**: Neurosterix's Series B financing. [3] [4]
- **5 startups**: Neurology companies that raised about $450 million combined in recent weeks. [6]

## Also published

- [STAT+: HHS plans funding for research into ibogaine for PTSD](<https://www.statnews.com/2026/11/13/biotech-news-hhs-funding-for-research-into-ibogaine-for-ptsd/?utm_campaign=rss>), STAT Biotech
- [Windward Bio catches $175m from its IPO](<https://pharmaphorum.com/news/windward-bio-catches-175m-its-ipo>), pharmaphorum
- [Neurosterix' $105m round leads the week's biotech financings](<https://pharmaphorum.com/news/neurosterix-105m-round-leads-weeks-biotech-financings>), pharmaphorum
- [Windward prices $175M IPO to advance China-licensed lung drugs](<https://www.biopharmadive.com/news/windward-ipo-pricing-immune-drugs-china-deals-tezspire/874533/>), BioPharma Dive

## Sources

1. [Windward raises $175M in IPO, adds $50M from Sanofi](<https://european-biotechnology.com/latest-news/windward-raises-175m-in-ipo-adds-50m-from-sanofi/>), European Biotechnology, 2026-11-13
2. [Windward Bio’s Stock Market Debut Reels In $225M for Better Biologic Drugs](<https://medcitynews.com/2026/11/windward-bio-ipo-long-acting-antibody-tslp-asthma-copd-atopic-dermatitis-wwb/>), MedCity News, 2026-11-13
3. [Neurosterix pockets $105m to advance neuropsychiatry pipeline ](<https://www.pharmaceutical-technology.com/news/neurosterix-150m-series-b-to-advance-neuropsychiatry-pipeline-schizophrenia/>), Pharmaceutical Technology, 2026-11-13
4. [Addex spinout Neurosterix raises $105M to advance schizophrenia drug into Phase 2](<https://european-biotechnology.com/latest-news/addex-spinout-neurosterix-raises-105m-to-advance-schizophrenia-drug-into-phase-2/>), European Biotechnology, 2026-11-12
5. [NIH is reorganizing clinical trial funding by trial type instead of disease](<https://www.drugdiscoverytrends.com/nih-is-reorganizing-clinical-trial-funding-by-trial-type-instead-of-disease/>), Drug Discovery and Development, 2026-11-13
6. [This week in charts: Brain drugs are back on venture’s minds](<https://www.biopharmadive.com/news/charts-venture-neuroscience-oyster-vectory-acr-cell-therapy/874570/>), BioPharma Dive, 2026-11-13

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://european-biotechnology.com/latest-news/windward-raises-175m-in-ipo-adds-50m-from-sanofi/>
[2]: <https://medcitynews.com/2026/11/windward-bio-ipo-long-acting-antibody-tslp-asthma-copd-atopic-dermatitis-wwb/>
[3]: <https://www.pharmaceutical-technology.com/news/neurosterix-150m-series-b-to-advance-neuropsychiatry-pipeline-schizophrenia/>
[4]: <https://european-biotechnology.com/latest-news/addex-spinout-neurosterix-raises-105m-to-advance-schizophrenia-drug-into-phase-2/>
[5]: <https://www.drugdiscoverytrends.com/nih-is-reorganizing-clinical-trial-funding-by-trial-type-instead-of-disease/>
[6]: <https://www.biopharmadive.com/news/charts-venture-neuroscience-oyster-vectory-acr-cell-therapy/874570/>
